ArticleFuture science OA2025
The prognostic impact of human epidermal growth factor receptor 2 status in metastatic colorectal cancer.
Article in Future science OA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Indirect comparisons of tucatinib in combination with trastuzumab for patients with previously treated HER2-positive metastatic colorectal cancer.Journal of comparative effectiveness research · 2026Article
- Review
- Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Colorectal Cancer and Its Clinical Significance among Jordanian Patients.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThis study evaluated the prognostic impact of human epidermal growth factor receptor 2 (HER2) status on real-world overall survival (rwOS) in patients with metastatic colorectal cancer (mCRC) who had not received HER2-targeted therapy.
methodsThis retrospective cohort analysis included patients diagnosed with mCRC from a US-based deidentified clinicogenomic CRC database between January 1, 2011, and March 31, 2023. Patients were evaluated based on HER2 status (HER2+ defined as documented
resultsAmong 7121 patients included in the study, 6948 (97.6%) had HER2- mCRC, and 173 (2.4%) had HER2+ mCRC. A higher number of HER2- patients had
conclusionHER2 status did not appear to impact rwOS. The findings from this study do not support a prognostic role for HER2 status in mCRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.